leisure time -WSS

leisure time

author：fashion 2025-10-02 13:40:59 - browse：2

Dallas Mavericks owner Mark Cuban reacts during a timeout in the game against the Golden State Warriors at American Airlines Center on March 22, 2023 in Dallas, Texas. – opinion coverage from STAT — Tim Heitman/Getty Images

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for alternatives to the status quo in the pharmaceutical industry.

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. But that might not be the case. Instead, its success appears to lie in its choice to collaborate with affordable generic drug manufacturers rather than the major pharmaceutical companies.

Last year, the Department of Health and Human Services found that between July 2021 and July 2022, major pharma companies raised the list price on more than 1,200 drugs by an average of 31 percent. That’s 23 percent more than the country’s overall inflation rate during the same period. Meanwhile, generic drug companies saved the U.S. roughly $2.6 trillion from 2012 to 2021, according to the Association for Accessible Medicines, a trade group representing generic drug manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Better Therapeutics data on benefit with GLP

leisure time

hotspot

WSS

Poor hospice wound care hurts patients and families

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Massive project maps cells in human brain in unprecedented detail

Massive project maps cells in human brain in unprecedented detail

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Peter Marks talks Operation Warp Speed for Rare Diseases

hotspot

leisure time

explore

Novavax promises a turnaround & Lilly roils the obesity market

NYU radiologists take on the challenge of expensive MRI machines

Tori Bowie and the unacceptable rates of Black maternal death

Astellas still sees hope in its gene therapy after four deaths

23andMe had bad news about my health. I wish a person had delivered it

Wellcome Trust names Røttingen as its new CEO

Medical records are filled with copy

Cancer cells are shown to suck energy source from immune cells

Novavax promises a turnaround & Lilly roils the obesity market

Wellcome Trust names Røttingen as its new CEO

Wikipedia

Humana CEO Bruce Broussard to step down in 2024

Takeaways from AdvaMed, the largest medical devices conference

Akero's treatment for NASH falls short in cirrhosis study

What's changing in Medicare's open enrollment this year?

Gain of function research would be limited under House proposal

A fraught question for the kids of Alzheimer’s: Is it coming for us?

leisure time

hotspot

focus

entertainment